Annual report
4483.TEDINET S100W76C
Period2024-04-01 → 2025-03-31
Filed2025-06-26
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 155
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥41.7bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥30.6bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥27.8bn | 2022-04-01 → 2023-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥21.8bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥16.8bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥8.7bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥5.5bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥8.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.9bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥4.8bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥7.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.3bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥3.2bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥7.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥4.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥143.0bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥122.5bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥98.6bn | at 2023-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥62.1bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥58.3bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥64.5bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥51.8bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥78.5bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥70.7bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥64.5bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥78.0bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥70.6bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥64.5bn | at 2023-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥31.2bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥28.3bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥32.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥22.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥19.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥14.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥17m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥4.1bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥3.8bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥3.2bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥3.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥24.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥9.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥16.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥28.3bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥18.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥111.34 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.76 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.17 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥57.74 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥46.54 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥110.23 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥69.95 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥67.69 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥54.16 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥43.48 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,192.97 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,080.51 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,025.89 | at 2023-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥551.17 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥504.59 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 54.6% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 57.6% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.5% | at 2023-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 48.8% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 9.8% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.8% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.9% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 10.9% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.0% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 2,187 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,773 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 1,346 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 966 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 757 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥12.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥11.5bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥9.4bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥8.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥6.3bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥696m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥1.9bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.1bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.9bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.7bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥4.1bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥82m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥3.1bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥429m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.3bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.2bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥734m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥103.9bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥90.9bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥73.2bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥41.4bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥42.5bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥40.3bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥30.0bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥63.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥60.9bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥59.8bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥29.3bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥27.8bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.3bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥47.56 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.69 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.08 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.54 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.8 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥47.08 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥20.2 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥12.89 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥16 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥972.76 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥931.64 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥950.74 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥517.6 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥497.17 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 61.2% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.0% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.7% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.7% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.0% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -0.7% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.7% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 65,373,808 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 65,331,208 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 62,910,608 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,514,208 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 55,935,808 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 488 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 431 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 348 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 305 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 265 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 31
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥41m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥41m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥861m |
| Healthcare Big Datareportable segment | employees | at 2025-03-31 | 2049 pure |
| Healthcare Big Datareportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥35.6bn |
| Healthcare Big Datareportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥35.6bn |
| Healthcare Big Datareportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥41m |
| Healthcare Big Datareportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥9.6bn |
| Tele Medicinereportable segment | employees | at 2025-03-31 | 134 pure |
| Tele Medicinereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Tele Medicinereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Tele Medicinereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥2.2bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥41.8bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥41.7bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥41m |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥11.8bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥64m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥64m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥747m |
| Healthcare Big Datareportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥25.1bn |
| Healthcare Big Datareportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥25.0bn |
| Healthcare Big Datareportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥64m |
| Healthcare Big Datareportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥7.9bn |
| Tele Medicinereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥5.6bn |
| Tele Medicinereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥5.6bn |
| Tele Medicinereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥2.1bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥30.6bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥30.6bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥64m |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥10.0bn |
| Healthcare Big Datareportable segment | employees | at 2025-03-31 | 488 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,731
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from short term borrowings fin cf IFRS | CurrentYearDuration | 300000000 | JPY |
| Repayments of short term borrowings fin cf IFRS | Prior1YearDuration | -264000000 | JPY |
| Repayments of short term borrowings fin cf IFRS | CurrentYearDuration | -16003000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1YearDuration | 2528000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | CurrentYearDuration | 32195000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YearDuration | -2606000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYearDuration | -7903000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YearDuration | -931000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYearDuration | -1154000000 | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | Prior1YearDuration | 2202000000 | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | CurrentYearDuration | 70000000 | JPY |
| Dividends paid fin cf IFRS | Prior1YearDuration | -754000000 | JPY |
| Dividends paid fin cf IFRS | CurrentYearDuration | -914000000 | JPY |
| Other fin cf IFRS | Prior1YearDuration | 5000000 | JPY |
| Other fin cf IFRS | CurrentYearDuration | -105000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YearDuration | 16581000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYearDuration | 6484000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | Prior1YearDuration | -8300000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | CurrentYearDuration | 17702000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 22782000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 14473000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YearDuration | -8000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYearDuration | -0 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 14473000000 | JPY |
| Cash and cash equivalents IFRS | CurrentYearInstant | 32176000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 24993000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 5579000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_ReportableSegmentsMember | 30572000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | Prior1YearDuration | 30572000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 64000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_ReportableSegmentsMember | 64000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_ReconcilingItemsMember | -64000000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration | － | JPY |
| Revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 25058000000 | JPY |
| Revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 5579000000 | JPY |
| Revenue IFRS | Prior1YearDuration_ReportableSegmentsMember | 30637000000 | JPY |
| Revenue IFRS | Prior1YearDuration_ReconcilingItemsMember | -64000000 | JPY |
| Revenue IFRS | Prior1YearDuration | 30572000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 7886000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 2075000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration_ReportableSegmentsMember | 9962000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration_ReconcilingItemsMember | -747000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration | 9214000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000HealthcareBigDataReportableSegmentMember | 1681000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_jpcrp030000-asr_E35308-000TeleMedicineReportableSegmentMember | 420000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_ReportableSegmentsMember | 2101000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_ReconcilingItemsMember | 0 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration | 2102000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |